Application of E_max model to assess the potency of topical corticosteroid products

Citations Over Time

Abstract

The objective of this study was to compare the potencies of two topical corticosteroid products (TCPs) using the E_max model to fit the skin blanching responses obtained from the US FDA's vasoconstrictor assay (VCA) and to illustrate the influence of formulation on potency. The potencies of two marketed TCPs, Dermovate® cream containing clobetasol propionate (CP) and Elocon® cream containing mometasone furoate (MF), were assessed using healthy human subjects. In order to investigate the influence of formulation and associated vehicle properties, the creams were compared with their respective topical corticosteroids (TCs) from a previously published study wherein the inherent potencies of those TCs were assessed using a validated VCA method. Whereas the inherent potency of MF (E_max = -94.45 ± 0.21) was found to be greater than CP (E_max = -58.80 ± 15.65), when formulated as creams, the TCP containing CP had a higher potency (E_max = -86.15 ± 0.17) than that containing MF (E_max = -42.61 ± 26.04). This reversal of potency may be attributed to the effect of formulation factors. The comparison of the potencies of TCPs with inherent potencies of their corresponding TCs confirmed the influence of formulation parameters on the potency of those products.

Related Papers

• → Comparative potency of formulations of mometasone furoate in terms of inhibition of ′PIRHR′ in the forearm skin of normal human subjects measured with laser doppler velocimetry(2005)9 cited
• The therapeutic efficacy of mometasone furoate cream 0.1% applied once daily vs clobetasol propionate cream 0.05% applied twice daily in chronic eczema.(1999)
• → Inhibition of Elicitation of Contact Dermatitis in Humans by Mometasone Furoate: Evaluation by Means of 20-MHz B Scanning Associated with Image Analysis(1997)14 cited
• → Mometasone furoate reduces oral corticosteroid requirements and improves hypothalamic-pituitary-adrenal axis function in patients with severe persistent asthma(2002)
• → The Effect of Mometasone Furoate/Formoterol Combination Treatment on Severe Exacerbations Requiring Hospitalization, Emergency Treatment, or Systemic Corticosteroid Treatment: Results From Two Randomized, Placebo-Controlled Studies(2010)